AMENDMENT NO. 3 TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 6th, 2019 • Zyla Life Sciences • Pharmaceutical preparations
This Amendment No. 3, dated as of May 31, 2019 (this “Amendment”) to the Asset Purchase Agreement (the “APA”), dated as of October 30, 2018, by and among Iroko Pharmaceuticals Inc., a business company incorporated in the British Virgin Islands (registration number 1732699) (the “Company”), Egalet US Inc., a Delaware corporation (“NewCo”), and Egalet Corporation, a Delaware corporation (“Buyer Parent”), as amended by Amendment No. 1, dated as of January 30, 2019, and by Amendment No. 2, dated as of January 31, 2019 (together with the APA and Amendment No. 1, the “Original Agreement”), is entered into by and among the Company, Newco and Buyer Parent. Capitalized terms used but not defined herein shall have the meanings assigned to them in the Original Agreement.
